P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Authors :: Jian-Rui Li
Di Ma
Puyuan Xing
Yongyan Wang
Guangjian Yang
Xuezhi Hao
Hao Xu
Source :: Journal of Thoracic Oncology. 13:S707
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Crizotinib
business.industry
Treatment duration
Internal medicine
ALK-Positive
medicine
business
medicine.drug

Full Text Access

Tools